

## Anti-Aging Active: Matrixyl

### Details:

Sederma Reports Major 6-Month in-vivo Anti-wrinkle Study:

Sederma reports it has just completed a 6-month long in-vivo double-blind study on the wrinkle assessment of the eye zone (i.e., crow's feet) to evaluate the effectiveness of the company's lipo-peptide MATRIXYL.



The study used profilometry (image analysis of skin) to measure the density, depth and volume of wrinkles around the eyes and consisted of treating the area and monitoring the changes over time. The study was conducted using a cream containing 3% MATRIXYL and involved two separate clinical trials, one comparing the MATRIXYL cream to a placebo cream, the other to a brand name product containing 5% Vitamin C. In every case, the company reports, the findings were statistically significant, saying treatment with the MATRIXYL cream produced a 50% decrease in wrinkle depth, a 68% decrease in wrinkle density and a 24% decrease in wrinkle volume. The in-vivo study is supported by separate ex-vivo studies that show MATRIXYL is more effective in stimulating collagen synthesis than Vitamin C or TGFb1.

MATRIXYL is a synthetic pentapeptide (Palmitoyl-Lys-Thr-Thr-Lys-Ser) that mimics a fragment of Procollagen Type I by stimulating the matrix molecules (Collagen I, III and IV and Fibronectin) to reduce the appearance of wrinkles.